Table 1 Summary of CTRCT events and related genetic determinants in studies investigating HER2 SNPs

Gómez Peña et al. [15]

1,136,201

(HER2 655 A > G)

78

28 (35.6%)

LVEF↓ > 10% resulting < 50%; or

LVEF↓ > 15%; or any LVEF↓, resulting < 45%; or CHF

9 (32.1%)

9/28 (32.1%)

6/50 (12%)

3.41

1.02–11.96

0.039

Beauclair et al. [16]

1,136,201

(HER2 655 A > G)

61

25 (41%)

LVEF↓ > 20%

5 (8.2%)

5/25 (20%)

0

NA

NA

0.004

Lemieux et al. [17]

1,136,201

(HER2 655 A > G)

73

21 (29%)

LVEF↓ > 10% resulting < 50%;

or any LVEF↓, resulting < 45%;

10 (13.7%)

6/21 (28.6%)

4/52 (7.7%)

4.67

1.01–19.94

0.028

Roca L et al. [2]

1,136,201

(HER2 655 A > G)

132

53 (40%)

Any LVEF↓ resulting < 50%; or LVEF↓ > 15%; or discontinuation of trastuzumab due to CTRCT

13 (9.8%)

9/53 (16.9%)

4/79 (5%)

3.79

1.09–14.01

0.026

Tan et al. [18]

1,136,201

(HER2 655 A > G)

91

27 (29.7%)

LVEF↓ > 10% resulting < 53%; or CHF; or ACS; or fatal arrhythmia

26 (28.6%)

13/27 (48.1%)

13 (20.3%)

7.99

1.79–35.76

0.007

Peddi et al. [19]

1,136,201

(HER2 655 A > G)

662

238 (35.5%)

LVEF↓ > 10%; or CHF

115 (17.3%)

47/238 (19.7%)

68/424

(16%)

NA

NA

0.65

Stanton et al. [20]

1,058,808

(HER2 1170 C > G)

140

111 (79.3%)

LVEF↓ > 15%; or CHF

29 (21%)

19/111 (17.1%)

10/29 (34.5%)

2.60

1.02–6.62

0.004

Boekhout et al. [21]

1,058,808

(HER2 1170 C > G)

206

NA

LVEF↓ > 15%; or LVEF < 45%

36 (17.4%)

NA

NA

0.09

0.02–0.45

0.003